STOCK TITAN

Electromed, Inc. Schedules its Second Quarter Fiscal 2024 Financial Results Conference Call for February 13, 2024 at 5:00 p.m. ET

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Electromed, Inc. announced the release of its financial results for the fiscal 2024 second quarter, with a conference call scheduled to discuss the results. The call will take place on February 13, 2024, at 5:00 p.m. Eastern Time, and interested parties can participate via phone or webcast. A replay of the call will also be available for those who cannot listen to the live broadcast.
Positive
  • None.
Negative
  • None.

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 second quarter ended December 31, 2023, on February 13, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1650986&tp_key=12e0064318

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13743606. Additionally, an online replay will be available in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com



Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Electromed, Inc.

FAQ

When will Electromed release its financial results for the fiscal 2024 second quarter?

Electromed will issue its financial results press release for the fiscal 2024 second quarter on February 13, 2024, after the close of the stock market.

How can interested parties participate in the conference call to discuss the results?

Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website.

Will there be a replay available for the conference call?

Yes, a replay of the conference call will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13743606. Additionally, an online replay will be available in the Investor Relations section of Electromed’s website.

Electromed, Inc.

NYSE:ELMD

ELMD Rankings

ELMD Latest News

ELMD Stock Data

141.78M
5.88M
26.7%
32.78%
0.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
NEW PRAGUE

About ELMD

electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.